Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Statistics
Want to see HK:9989 full AI Analyst Report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Stock Statistics & Valuation Metrics
Total Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has a market cap or net worth of HKD 14.27B. The enterprise value is HKD 4.32B.
- Market Cap
- HKD 14.27B
- Enterprise Value
- HKD 4.32B
Share Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 220,094,500
- Owned by Insiders
- ―
- Owned by Institutions
- 0.98%
Financial Efficiency
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.75%.
- Return on Equity (ROE)
- 0.03
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 3.75%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 2.55M
- Profits Per Employee
- 162.55K
- Employee Count
- 2,150
- Asset Turnover
- 0.33
- Inventory Turnover
- 0.84
Valuation Ratios
The current PE Ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is 69.83. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s PEG ratio is -1.27.
- PE Ratio
- 69.83
- PS Ratio
- 2.39
- PB Ratio
- 1.11
- Price to FCF
- 6.58
- Price to Operating Cash Flow
- 6.87
- PEG Ratio
- -1.27
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H had revenue of 5.48B and earned 349.49M in profits. Earnings per share was 0.24.
- Revenue
- 5.48B
- Gross Profit
- 1.74B
- Operating Income
- 635.97M
- Pretax Income
- 402.24M
- Net Income
- 349.49M
- EBITDA
- 846.59M
- Earnings Per Share (EPS)
- 0.24
Cash Flow
In the last 12 months, operating cash flow was 1.77B and capital expenditures -105.55M, giving a free cash flow of 1.67B billion.
- Operating Cash Flow
- 1.77B
- Free Cash Flow
- 1.67B
- Free Cash Flow per Share
- 1.26
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays an annual dividend of HKD 0.27, resulting in a dividend yield of 4.13%
- Dividend Per Share
- HKD 0.27
- Dividend Yield
- 4.13%
- Payout Ratio
- 86.79%
- Free Cash Flow Yield
- 15.19%
- Earnings Yield
- 1.42%
Stock Price Statistics
- Beta
- 0.71
- 52-Week Price Change
- -29.47%
- 50-Day Moving Average
- 3.98
- 200-Day Moving Average
- 4.39
- Relative Strength Index (RSI)
- 53.20
- Average Volume (3m)
- 535.50K
Important Dates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- May 26, 2025
Financial Position
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H as a current ratio of 2.31, with Debt / Equity ratio of 17.53%
- Current Ratio
- 2.31
- Quick Ratio
- 1.19
- Debt to Market Cap
- 0.30
- Net Debt to EBITDA
- 0.90
- Interest Coverage Ratio
- 8.90
Taxes
In the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has paid 59.60M in taxes.
- Income Tax
- 59.60M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H EV to EBITDA ratio is 29.73, with an EV/FCF ratio of 7.35.
- EV to Sales
- 2.66
- EV to EBITDA
- 29.73
- EV to Free Cash Flow
- 7.35
- EV to Operating Cash Flow
- 6.95
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has HKD 4.27B in cash and marketable securities with HKD 2.86B in debt, giving a net cash position of HKD 1.41B billion.
- Cash & Marketable Securities
- HKD 4.27B
- Total Debt
- HKD 2.86B
- Net Cash
- HKD 1.41B
- Net Cash Per Share
- HKD 6.40
- Tangible Book Value Per Share
- HKD 6.55
Margins
Gross margin is 33.50%, with operating margin of 8.91%, and net profit margin of 3.74%.
- Gross Margin
- 33.50%
- Operating Margin
- 8.91%
- Pretax Margin
- 3.33%
- Net Profit Margin
- 3.74%
- EBITDA Margin
- 8.96%
- EBIT Margin
- 5.14%
Analyst Forecast
The average price target for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -1.32%
- EPS Growth Forecast
- -50.00%
Scores
- Smart Score
- 4
- AI Score
- 56

